266 related articles for article (PubMed ID: 33968675)
21. Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications.
Kurtis B; Zhuge J; Ojaimi C; Ye F; Cai D; Zhang D; Fallon JT; Zhong M
Ann Diagn Pathol; 2016 Apr; 21():7-11. PubMed ID: 27040924
[TBL] [Abstract][Full Text] [Related]
22. Accurate detection of upper tract urothelial carcinoma in tissue and urine by means of quantitative GDF15, TMEFF2 and VIM promoter methylation.
Monteiro-Reis S; Leça L; Almeida M; Antunes L; Monteiro P; Dias PC; Morais A; Oliveira J; Henrique R; Jerónimo C
Eur J Cancer; 2014 Jan; 50(1):226-33. PubMed ID: 24100025
[TBL] [Abstract][Full Text] [Related]
23. Tumor volume determines the feasibility of cell-free DNA sequencing for mutation detection in non-small cell lung cancer.
Ohira T; Sakai K; Matsubayashi J; Kajiwara N; Kakihana M; Hagiwara M; Hibi M; Yoshida K; Maeda J; Ohtani K; Nagao T; Nishio K; Ikeda N
Cancer Sci; 2016 Nov; 107(11):1660-1666. PubMed ID: 27575703
[TBL] [Abstract][Full Text] [Related]
24. Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations.
Palsgrove DN; Taheri D; Springer SU; Cowan M; Guner G; Mendoza Rodriguez MA; Rodriguez Pena MDC; Wang Y; Kinde I; Ricardo BFP; Cunha I; Fujita K; Ertoy D; Kinzler KW; Bivalacqua TJ; Papadopoulos N; Vogelstein B; Netto GJ
Hum Pathol; 2019 Mar; 85():1-9. PubMed ID: 30447301
[TBL] [Abstract][Full Text] [Related]
25. No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer.
Otto W; Denzinger S; Bertz S; Gaumann A; Wild PJ; Hartmann A; Stoehr R
Int J Cancer; 2009 Nov; 125(9):2205-8. PubMed ID: 19621447
[TBL] [Abstract][Full Text] [Related]
26. Development of a Sensitive Digital Droplet PCR Screening Assay for the Detection of
Jain M; Tivtikyan A; Kamalov D; Avdonin S; Rakhmatullin T; Pisarev E; Zvereva M; Samokhodskaya L; Kamalov A
Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831030
[TBL] [Abstract][Full Text] [Related]
27. Why are upper tract urothelial carcinoma two different diseases?
Szarvas T; Módos O; Horváth A; Nyirády P
Transl Androl Urol; 2016 Oct; 5(5):636-647. PubMed ID: 27785420
[TBL] [Abstract][Full Text] [Related]
28. Comparison of clinicopathological features in metastatic upper tract urothelial carcinoma and urothelial bladder cancer.
Xie J; Zhang XB; Wen J; Zhang YS; Li HZ
Int Urol Nephrol; 2016 Apr; 48(4):481-7. PubMed ID: 26797856
[TBL] [Abstract][Full Text] [Related]
29. A Urine-Based Liquid Biopsy Method for Detection of Upper Tract Urinary Carcinoma.
Xu Y; Ma X; Ai X; Gao J; Liang Y; Zhang Q; Ma T; Mao K; Zheng Q; Wang S; Jiao Y; Zhang X; Li H
Front Oncol; 2020; 10():597486. PubMed ID: 33634022
[TBL] [Abstract][Full Text] [Related]
30. H-RAS mutation is a key molecular feature of pediatric urothelial bladder cancer. A detailed report of three cases.
Castillo-Martin M; Collazo Lorduy A; Gladoun N; Hyun G; Cordon-Cardo C
J Pediatr Urol; 2016 Apr; 12(2):91.e1-7. PubMed ID: 26522772
[TBL] [Abstract][Full Text] [Related]
31. Prognostic Genetic Signatures in Upper Tract Urothelial Carcinoma.
Li Q; Bagrodia A; Cha EK; Coleman JA
Curr Urol Rep; 2016 Feb; 17(2):12. PubMed ID: 26757906
[TBL] [Abstract][Full Text] [Related]
32. Molecular changes during progression from nonmuscle invasive to advanced urothelial carcinoma.
Sjödahl G; Eriksson P; Patschan O; Marzouka NA; Jakobsson L; Bernardo C; Lövgren K; Chebil G; Zwarthoff E; Liedberg F; Höglund M
Int J Cancer; 2020 May; 146(9):2636-2647. PubMed ID: 31609466
[TBL] [Abstract][Full Text] [Related]
33. Small-cell Carcinomas of the Urinary Bladder and Prostate: TERT Promoter Mutation Status Differentiates Sites of Malignancy and Provides Evidence of Common Clonality Between Small-cell Carcinoma of the Urinary Bladder and Urothelial Carcinoma.
Priemer DS; Wang M; Zhang S; Lopez-Beltran A; Kouba E; Montironi R; Davidson DD; MacLennan GT; Wang L; Osunkoya AO; Deng Y; Emerson RE; Cheng L
Eur Urol Focus; 2018 Dec; 4(6):880-888. PubMed ID: 28753872
[TBL] [Abstract][Full Text] [Related]
34. Molecular identification of telomerase reverse transcriptase (TERT) promotor mutations in primary and recurrent tumors of invasive and noninvasive urothelial bladder cancer.
Roggisch J; Ecke T; Koch S
Urol Oncol; 2020 Mar; 38(3):77.e17-77.e25. PubMed ID: 31521529
[TBL] [Abstract][Full Text] [Related]
35. Clinical utility and concordance of upper urinary tract cytology and biopsy in predicting clinicopathological features of upper urinary tract urothelial carcinoma.
Simon CT; Skala SL; Weizer AZ; Ambani SN; Chinnaiyan AM; Palapattu G; Hafez K; Magers MJ; Kaffenberger SD; Spratt DE; Montgomery JS; Morgan TM; Udager AM; Lew M; Mehra R
Hum Pathol; 2019 Apr; 86():76-84. PubMed ID: 30537495
[TBL] [Abstract][Full Text] [Related]
36. Urine Biopsy-Liquid Gold for Molecular Detection and Surveillance of Bladder Cancer.
Satyal U; Srivastava A; Abbosh PH
Front Oncol; 2019; 9():1266. PubMed ID: 31803629
[TBL] [Abstract][Full Text] [Related]
37. [Methylation status of RASSF1A gene promoter in upper tract urothelial carcinoma and its clinical significance].
Liu J; Xiong GY; Tang Q; Fang D; Li XS; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Aug; 48(4):571-578. PubMed ID: 29263491
[TBL] [Abstract][Full Text] [Related]
38. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
[TBL] [Abstract][Full Text] [Related]
39. Clinical Application of
Hayashi Y; Fujita K; Netto GJ; Nonomura N
Front Oncol; 2021; 11():705440. PubMed ID: 34395278
[TBL] [Abstract][Full Text] [Related]
40. Differences in the genomic profiles of cell-free DNA between plasma, sputum, urine, and tumor tissue in advanced NSCLC.
Wu Z; Yang Z; Li CS; Zhao W; Liang ZX; Dai Y; Zhu Q; Miao KL; Cui DH; Chen LA
Cancer Med; 2019 Mar; 8(3):910-919. PubMed ID: 30767431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
